Palatin Technologies: Potential Phase 3 Clinical Study in Ed Patients Who Do Not Respond to Pde5I Monotherapy to Start in H1 2025
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.